MISSISSAUGA, ON, Oct. 24, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2018 financial results conference call on Wednesday, November 7, 2018. The call will be hosted by Robert Tessarolo, President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer. The Company will issue its financial results on the morning of November 7, 2018.
CONFERENCE CALL DETAILS
Wednesday, November 7, 2018
8:30 a.m. EST
DIAL IN NUMBER:
(416) 764-8609 or (888) 390-0605
(416) 764 8677 or (888) 390-0541 (playback code 175672)
The audio webcast can be accessed at http://cipher.investorroom.com/ under Investor Relations or at https://event.on24.com/wcc/r/1865375/ECD67237F8B0A2DCCC17B86659CF5B78
About Cipher Pharmaceuticals Inc.
Cipher (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. Cipher is focused on a three-pronged growth strategy – including acquisitions, in-licensing, and selective investments in drug development – to assemble a broad portfolio of prescription products that serve unmet medical needs. For more information, visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.